NLRP3 and melanoma: NLRP3 inhibition diminished PMN-MDSC recruitment in response to anti-PD-1 Ab therapy in a mouse melanoma model (75, 76), and NLRP3 inflammasome blockade reduced the frequencies of MDSCs in the tumor tissues, spleen, and peripheral blood in lymphoma and decreased the expression of immunosuppressive genes (Pdcd1l1, Arg1, Il10, and Tgfb1) in PMN-MDSCs isolated from tumor-bearing mice (77, 78).